Achieve faster time to targeted therapy — Species identification within 3 to 5 hours of first blood draw
Sepsis is one of the top five diagnoses for adult admissions in the ICU1
During an individual stay in the Intensive Care Unit (ICU), sepsis is identified in 29.5% of patients,² with high mortality rates for those with bloodstream infections (BSIs) that range from 26% to 47%.³
Blood cultures are routinely ordered for sepsis patients in the ICU, but they have certain limitations, including inconsistent results due to slow growth⁴, interference from previously administered antimicrobials, and difficulty with identifying polymicrobial infections.⁵
Culture-Independent Diagnostics for Sepsis
T2 Biosystems Sepsis Panels
T2 Biosystems has developed the first and only diagnostic test panels to provide species identification directly from a whole blood sample without waiting for a positive blood culture. The T2Bacteria® and T2Candida® Panels are run on the fully automated T2Dx® Instrument and are powered by T2 Magnetic Resonance (T2MR®) Technology.
With results in as little as 3 to 5 hours, physicians can target therapy before the second dose of empiric therapy has been administered. When every hour counts, T2Bacteria and T2Candida can provide rapid species identification for bacterial and fungal infections before the blood culture turns positive, enabling timely and targeted treatment for better patient outcomes.
A T2Bacteria result facilitated the diagnosis of infective endocarditis that led to rapid initiation of targeted antibiotic therapy in a critically ill patient with prosthetic valve endocarditis. Fast species ID enabled targeted treatment 8 days before blood culture results were available.
Barrett, ML, et al. Agency for Healthcare Research and Quality. 2014.
Sakr, Y, et al. Open Forum Infect Dis. 2018
Wisplinghoff, H, et al. Clin Infect Dis. 2004
Bourbeau, PP, et al. J Clin Microbiol. 2005
Doualeh, et al. Int J Mol Sci. 2022
Giannella, M, et al. Expert Rev. of Med. Dev. 2021
Nguyen, M. H., et al. Annals of Internal Medicine. 2019
Clancy, N., et al. Clin Infect. Dis. 2018
T2Bacteria Instructions for Use
T2Candida Instructions for Use
Mylonakis, E., et al. Clinical Infectious Diseases. 2015
JOIN THE MAILING LIST!
T2 BIOSYSTEMS OVERVIEW
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.